Clinical trial Recruiting at 1 site Interventional Ages 10 to 14

Clear thermoplastic maxillary expander versus Hyrax for adolescents

Official title: Evaluating the Clinical Performance of a Novel Clear Orthodontic Expander Versus Hyrax: A Randomized Clinical Trial

Run by University of Baghdad · NCT07362160 · Data updated 2026-11-12

This will test whether a clear PETG thermoplastic expander with an integrated screw works as well as a Hyrax expander to widen the upper jaw in adolescents (ages 10–14) with a narrow maxilla.

Quick facts

Study typeInterventional
Ages10 Years to 14 Years
SexAll
Enrollment40 (estimated)
SponsorUniversity of Baghdad
Academic / other
Locations1 site (Baghdad, Al-Rusafa, Bab Al-moadham)
StatusRecruiting
StartedFebruary 1, 2026
Main results expectedNovember 1, 2026
Study endsFebruary 1, 2027
Registry record updatedApril 22, 2026
Trial IDNCT07362160 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are healthy adolescents aged 10–14 with a posterior crossbite from maxillary constriction, fully erupted first molars, and good oral and general health.

Probably not a fit

Patients with obvious facial asymmetry, orofacial clefts, prior orthodontic treatment, bad oral habits, active periodontal disease, or outside the 10–14 age range are unlikely to benefit from this intervention.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, randomized, two-arm parallel trial comparing a 2-mm PETG clear expander with an integrated expansion screw to the conventional Hyrax expander in adolescents. About 20 patients per group (allowing for dropouts) will be enrolled at the University of Baghdad College of Dentistry and affiliated centers, with randomization for both expander type and for one of two cleaning methods for the clear device. Outcomes include CBCT measures of skeletal and dental expansion, intraoral scans, cephalometric angles, microbial counts related to cleaning method, and patient experience/satisfaction questionnaires. Clinically effective expansion is defined as 2.5 mm or greater of maxillary sutural opening.

Why it matters

Potential benefit: If successful, the clear PETG expander could provide equivalent maxillary expansion while offering better esthetics and possibly greater comfort and hygiene options for adolescent patients.

How similar studies have gone: Related clear or removable expander approaches have shown some success in dental expansion, but this specific PETG thermoplastic design with an integrated screw is relatively new and evidence is limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Patients' age at the start of treatment will range from 10-14 years.
2. Unstable unilateral or bilateral posterior crossbite due to maxillary constriction.
3. The first molars are fully erupted.
4. Good oral health free from caries and periodontal problems at the start of treatment.
5. Good general health.

Exclusion Criteria:

1. Patients with obvious facial asymmetry.
2. Patients with orofacial cleft.
3. Patients with previous orthodontic treatment.
4. Patients with bad oral habits.
5. Patients with active periodontal disease.

Where it's running

  • University of Baghdad/Collage of Dentistry
    Baghdad, Al-Rusafa, Bab Al-moadham, Iraq
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.